Why is Syngene International Ltd falling/rising?

Recent Price Movement and Market Performance

Syngene’s stock has been under significant pressure over the past week, declining by 13.74%, which starkly contrasts with the Sensex’s modest 2.43% fall during the same period. The downward momentum extends over the last month and year, with the stock losing 17.84% and 36.15% respectively, while the Sensex has gained 6.56% over the year. This persistent underperformance highlights investor concerns about the company’s fundamentals and growth prospects.

On the day in question, the stock hit a new 52-week low of ₹539.05, trading within a wide intraday range of ₹58.5. The opening price was down 2.08%, and the weighted average price indicated that most volume was transacted near the day’s low, signalling selling pressure. Additionally, the stock has now declined for eight consecutive sessions, losing nearly 14.7% in that span, underscoring a sustained bearish sentiment.

Technical Indicators and Trading Activity

Technically, Syngene is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. The stock also exhibited high intraday volatility of 5.47%, reflecting uncertainty and active trading. Notably, investor participation has increased, with delivery volumes rising by over 53% compared to the five-day average, suggesting that more investors are offloading shares amid the decline.

Fundamental Challenges Weighing on the Stock

Syngene’s recent quarterly results have been a key catalyst for the share price decline. The company reported a profit before tax excluding other income of ₹83.60 crores, down 37.8% compared to the average of the previous four quarters. Net profit after tax fell even more sharply by 55.3% to ₹52.29 crores, with earnings per share dropping to a low of ₹0.37. These figures indicate a significant slowdown in profitability, which has understandably unsettled investors.

Over the longer term, Syngene’s growth has been modest at best. Net sales have increased at an annual rate of 12.63% over the past five years, while operating profit has grown at just 9.01% annually. Such growth rates are relatively subdued for a company in the pharmaceutical research and development sector, where higher expansion is often expected. This tepid growth, combined with declining recent profits, has contributed to the stock’s poor performance.

Valuation Concerns and Relative Performance

Despite the weak earnings, Syngene trades at a premium valuation, with a price-to-book ratio of 4.6 and a return on equity of 9.9%. This valuation is expensive relative to its peers and historical averages, which may deter value-conscious investors. The stock’s premium pricing appears unjustified given the deteriorating profitability and lacklustre growth, leading to a disconnect between price and fundamentals.

Furthermore, Syngene has underperformed not only the Sensex but also the broader BSE500 index over multiple time frames, including the last three years, one year, and three months. This consistent underperformance highlights the challenges the company faces in delivering shareholder value compared to the wider market and its sector.

Institutional Holdings and Debt Profile

On a positive note, Syngene maintains a low debt-to-equity ratio, effectively zero, which reduces financial risk. Additionally, institutional investors hold a significant 40.8% stake in the company, suggesting that knowledgeable market participants continue to back the stock despite recent setbacks. However, even this support has not been sufficient to arrest the recent decline, as concerns over earnings and valuation dominate investor sentiment.

Conclusion

In summary, Syngene International Ltd’s share price is falling due to a combination of disappointing quarterly earnings, weak long-term growth, and an expensive valuation relative to its fundamentals. The stock’s sustained underperformance against market benchmarks and technical indicators further compounds negative sentiment. While the company’s strong institutional backing and clean balance sheet offer some reassurance, these factors have not offset the impact of deteriorating profitability and investor caution. As a result, the stock remains under pressure, reflecting the market’s reassessment of Syngene’s growth prospects and value proposition.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →